会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • INFLUENZA THERAPEUTIC
    • 流感治疗
    • US20100204297A1
    • 2010-08-12
    • US11909413
    • 2006-03-22
    • Jianzhu ChenQing GeHerman N. Eisen
    • Jianzhu ChenQing GeHerman N. Eisen
    • A61K31/713C07K7/08C07K14/00A61P31/16C12N15/63
    • A61K9/5146A61K9/5153A61K38/00C12N15/111C12N15/1131C12N2310/111C12N2310/14C12N2310/321C12N2310/53C12N2320/11C12N2320/32C12N2799/021C12N2310/3521
    • The present invention provides compositions comprising an RNAi-inducing entity targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for inhibiting a biological activity of an influenza virus and/or for treatment or prevention of influenza. The invention provides target portion sequences that are favorably conserved for RNAi across a plurality of influenza virus A strains isolated from human hosts and/or avian hosts and RNAi-inducing entities, e.g., siRNAs and shRNAs, targeted to such favorably conserved target portions. The invention provides a variety of nucleic acids comprising sequences identical or complementary to at least a portion of one or more of these favorably conserved target portion sequences. The invention further provides methods and compositions for delivering RNAi-inducing agents to an organ or tissue of a mammalian subject, e.g., to the lung. Methods of diagnosing influenza and determining the susceptibility of an influenza virus to inhibition by an RNAi-inducing agent are also provided. Transgenic animals that express an RNAi-inducing agent targeted to an influenza gene are another aspect of the invention.
    • 本发明提供了包含针对流感病毒转录物的RNAi诱导实体和各种递送试剂中的任一种的组合物。 本发明还包括使用该组合物抑制流感病毒的生物学活性和/或用于治疗或预防流感的方法。 本发明提供了针对分离自人宿主和/或禽类宿主和RNAi诱导实体(例如siRNA和shRNA)的多个流感病毒A菌株的RNAi有利地保守的靶标部分序列,靶向这些有利的保守靶部分。 本发明提供了多种核酸,其包含与这些有利保守的靶部分序列中的一种或多种的至少一部分相同或互补的序列。 本发明进一步提供了将哺乳动物受试者的器官或组织例如向肺部递送RNAi诱导剂的方法和组合物。 还提供了诊断流感和确定流感病毒对RNAi诱导剂抑制的易感性的方法。 表达靶向流感基因的RNAi诱导剂的转基因动物是本发明的另一方面。
    • 5. 发明授权
    • Antisense antiviral compound and method for treating influenza viral infection
    • 反义抗病毒化合物及治疗流感病毒感染的方法
    • US08357664B2
    • 2013-01-22
    • US11259434
    • 2005-10-25
    • David A. SteinQing GeJianzhu ChenPatrick L. IversenHong M. Moulton
    • David A. SteinQing GeJianzhu ChenPatrick L. IversenHong M. Moulton
    • A61K48/00
    • C12N15/1131C12N2310/3145C12N2310/3233C12N2310/3513
    • The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3′ terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA.
    • 本发明提供反义抗病毒化合物及其在抑制正粘病毒科的病毒生长和用于病毒感染治疗中的用途和生产方法。 该化合物特别可用于治疗哺乳动物的流感病毒感染。 反义抗病毒化合物是具有1)核酸酶抗性主链,2)12-40个核苷酸碱基的基本上不带电荷的吗啉代寡核苷酸,和3)长度为至少12个碱基的靶向序列与选自以下的靶区域杂交: )流感病毒A,流感病毒B和流感病毒C的负义病毒RNA片段的5'或3'末端25个碱基; b)正义cRNA的3'末端的末端25个碱基; 和c)围绕流感病毒mRNA的AUG起始密码子的50个碱基。
    • 8. 发明申请
    • RNAi-BASED THERAPEUTICS FOR ALLERGIC RHINITIS AND ASTHMA
    • 用于过敏性RHINITIS和ASTHMA的基于RNAi的治疗方法
    • US20110112169A1
    • 2011-05-12
    • US12891626
    • 2010-09-27
    • Jianzhu ChenHerman N. EisenQing Ge
    • Jianzhu ChenHerman N. EisenQing Ge
    • A61K31/713C07H21/02A61K31/7105A61P11/00A61P11/06C12N15/63
    • C12N15/113C12N15/111C12N15/1137C12N15/1138C12N2310/111C12N2310/14C12N2310/53C12N2320/32
    • The present invention provides compositions comprising one or more RNAi agents (e.g., siRNAs, shRNAs, or RNAi vectors) for the treatment of conditions and diseases mediated by (e.g., featuring IgE-mediated hypersensitivity), as well as systems for identifying RNAi agents effective for this purpose. The compositions are suitable for the treatment of allergic rhinitis and/or asthma. In certain embodiments of the invention the RNAi agent is targeted to a transcript that encodes a protein selected from the group consisting of the FCεRIα chain, the FCεRIβ chain, c-Kit, Lyn, Syk, ICOS, OX40L, CD40, CD80, CD86, Re1A, Re1B, 4-1BB ligand, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, CD83, SLAM, common γ chain, and COX-2. In addition, the invention provides RNAi agent/delivery agent compositions and methods of use. In certain embodiments of the invention compositions comprising an RNAi agent are delivered by the respiratory route.
    • 本发明提供包含用于治疗由(例如,特征为IgE介导的超敏反应)介导的病症和疾病的一种或多种RNAi剂(例如siRNA,shRNA或RNAi载体)的组合物,以及用于鉴定有效的RNAi剂的系统 以此目的。 该组合物适用于治疗过敏性鼻炎和/或哮喘。 在本发明的某些实施方案中,所述R​​NAi试剂靶向编码选自下组的蛋白质的转录物:FC&RIα链,FC& RI&bgr; 链,c-Kit,Lyn,Syk,ICOS,OX40L,CD40,CD80,CD86,Re1A,Re1B,4-1BB配体,TLR1,TLR2,TLR3,TLR4,TLR5,TLR6,TLR7,TLR8,TLR9,CD83,SLAM ,普通γ链和COX-2。 此外,本发明提供RNAi剂/递送剂组合物和使用方法。 在本发明的某些实施方案中,包含RNAi试剂的组合物通过呼吸途径递送。